Skip to the page

Data / Form D filings / Remix Therapeutics, Inc.

Remix Therapeutics, Inc.: Form D filing

Remix Therapeutics, Inc., a biotechnology company in Watertown, MA, filed a Form D with the SEC in 2024. The latest, on January 4, 2024, reports $13.7 million sold of a $90 million offering to 21 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
100 FORGE ROAD, Watertown, MA, 02472
Phone
(781) 827-0901
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2019
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2006953

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Jan 4, 2024New notice$90,000,000$13,740,355$76,259,64521Dec 22, 2023sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Peter SmithExecutive Officer, Director
Robert GagnonExecutive Officer
Matthew PattersonDirector
Kevin BittermanDirector
Jeff GoaterDirector
Michael RomeDirector
Scott BillerDirector
Heather WassermanExecutive Officer

Other biotechnology companies in Massachusetts that filed recently

Every Form D from the week of Jan 1, 2024 · All recent filings in Massachusetts · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Remix Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.